Skip to content

DEVELOPMENT pipeline

34 Projects
18 Phase 1
6 Phase 2
6 Phase 3
4 Registration

Oncology

SOLID TUMORS

Compound / MOA
Project
Therapeutic area
Phase
FTD/TPI + bevacizumab
S95005
Solid tumors (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US/CAN, MEX & Asia
Partner
FTD/TPI + futuximab / modotuximab
S95026
Solid tumors (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US/CAN, MEX & Asia
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Anti-MET
S95027
Non small Cell Lung Cancer
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Vorasidenib + anti-PD1
S95032
Grade 2-3 glioma with IDH1/2 mutation
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Ivosidenib en association
S95031
Solid tumors (new indication)
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Anti-TIM3, anti-PD1, + irinotécan
S95018
2nd line Biliary Tract Cancer and Esophageal squamous cell carcinoma
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Anti-CD73
S95024
Solid tumors
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Anti-PD-L1/4-1BB
S95012
Solid tumors
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US
Partner
Anti-NKG2A
S95029
Solid tumors
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Inhibiteur de MAT2A
S95035
Solid tumors
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Anti-FLT3
S95040
Solid tumors
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide

HEMATOLOGICAL MALIGNANCIES

Compound / MOA
Project
Therapeutic area
Phase
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Partner
Licencié en Chine
UCART 19
S68587/S95023
Hematological malignancies
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US
Partner
Calaspargase pegol
S95015
Hematological malignancies (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Pegaspargase
S95014
Hematological malignancies (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Ivosidenib
S95031
Hematological malignancies (new indication)
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Partner
Licencié en Chine
Inhibiteur de BCL-2
S65487
Acute Myeloid Leukemia
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US/CAN, JAP, some EU countries
Partner
Inhibiteur de Mcl1
S64315
Hematological malignancies
DPC
1/2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US/CAN, JAP, some EU countries
Partner
Inhibiteur de Mcl1
S216096
Hematological malignancies
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide ex-US/CAN, JAP, some EU countries
Partner

Cardiometabolism

Compound / MOA
Project
Therapeutic area
Phase
NRF2
S227879
Non alcoholic steatohepatitis
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide

Neuroscience

Compound / MOA
Project
Therapeutic area
Phase
Agomelatin
S20098
Psychiatry (new indication)
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
LRRK2
S221237
Parkinson’s Disease
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Partner

Immuno-inflammation

Compound / MOA
Project
Therapeutic area
Phase
Anti-IL7R
S95011
Sjögren syndrome
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Partner
Anti-IL7R
S95011
Ulcerative colitis
DPC
1
2
3
flèche d’ouverture / fermeture
Territory
Worldwide
Partner

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3; FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor; MTAP: Methylthioadenosine Phosphorylase; IDH: Isocitrate dehydrogenase; AYA: Adolescents and Young Adults; MOA: Mode of Action